Peter Young


Biopharma Stock Check: Market Review and Outlook

Exploring the pharma and biotech financing, M&A, and stock market pictures through the first half of 2023—and implications for the future, as market challenges continue to weigh heavily in senior management decision-making.

Biopharma M&A: Year in Review, Ripples Ahead

While industry financial markets continued to experience subdued dollar volumes in 2022, dealmaking held steady—with factors such as pharma pursuing strategic priorities and biotech funding woes playing major roles.